Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor.

MLA

Shi, Zi‐Yang, et al. “Molecular Heterogeneity of BCL2/MYC Double Expressor Lymphoma Underlies Sensitivity to Histone Deacetylase Inhibitor.” Clinical & Translational Medicine, vol. 14, no. 6, June 2024, pp. 1–7. EBSCOhost, https://doi.org/10.1002/ctm2.1691.

APA

Shi, Z., Fang, Y., Xu, P., Yi, H., Li, J., Dong, Y., Zhu, Y., Liu, M., Fu, D., Wang, S., Shi, Q., Shen, R., Zhong, H., Wang, C., Cheng, S., Wang, L., Liu, F., & Zhao, W. (2024). Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor. Clinical & Translational Medicine, 14(6), 1–7. https://doi.org/10.1002/ctm2.1691

Chicago

Shi, Zi‐Yang, Ying Fang, Peng‐Peng Xu, Hong‐Mei Yi, Jian‐Feng Li, Yan Dong, Yue Zhu, et al. 2024. “Molecular Heterogeneity of BCL2/MYC Double Expressor Lymphoma Underlies Sensitivity to Histone Deacetylase Inhibitor.” Clinical & Translational Medicine 14 (6): 1–7. doi:10.1002/ctm2.1691.